FDA clears new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol
“Today’s IND to expand the potential indications for GTB-5550 highlights the diverse utility of our Trike® platform,” said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma. “The company remains focused on its two ongoing Phase 1 trials with GTB-5550 and GTB-3650, both of which are actively enrolling, and we look forward to the potential initiation of a third Phase 1 trial, pending receipt of non-dilutive grant funding.”
Share:
More News
Akeso, Inc. announced that AK158D1, its investigational next-generation bispecific antibody-drug conjugate (ADC) targeting EGFR and TROP2, has secured Phase I clinical trial clearance from the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA). The trial will assess the candidate in patients with advanced malignant solid tumors.
“This financing marks a significant milestone as we execute upon our vision of harnessing the power of macrocycles to transform the treatment of cancer,” said David J. Earp, J.D., Ph.D., president and chief executive officer of Circle Pharma. “Momentum around our cyclin D1 program has continued to build as CID-165
“FDA Fast Track designation for KST-6051 is an important regulatory milestone for Kestrel, based on the strength of our preclinical data package. This designation will allow us to work more closely with the FDA as we advance KST-6051 through our ongoing Phase 1 study, with the goal of bringing a
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “Today’s deal secures a promising T cell engager and advances GSK’s leadership goals in blood cancer. The agreement complements our existing portfolio in multiple myeloma, adding a new potential option to address the different needs of patients facing this